drugset / Trial / NCT01712256

Re-boosting of HIV-1 Infected Subjects With Vacc-4x

NCT01712256

Phase 2 Completed 33 enrolled Bionor Immuno AS
NaSingle-groupOpen-labelTreatment

Summary

During the course of HIV infection the number of CD4 cells decreases, resulting in a reduced immunological response and eventually immune deficiency. Vacc-4x is a peptide-based HIV immunotherapy vaccine and is anticipated to strengthen the immune system's response to HIV. All patients participating in this trial have previously received the vacc-4x vaccine in order to reduce the amount of HIV-1 virus in the blood and increase the immune response. The primary objective of this study is to evaluate if a re-boost with Vacc-4x could further reduce the amount of HIV-1 virus and increase the immune response.

Timeline

Start
2012-12
Primary completion
2014-01
Completion
2014-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Vacc-4x Peptide 1.2 mg Other